FDA Launches Unified Adverse Event Analysis Platform AEMS

Sat, 14 Mar 2026 15:49:42 +0000
Healthcare

The FDA has launched a new unified platform, the Adverse Event Monitoring System (AEMS), to analyze adverse event reports for all regulated products. This modernization aims to improve data accessibility, transparency, and surveillance capabilities, replacing fragmented legacy systems and is expected to save $120 million over five years.